论文部分内容阅读
目的观察白介素—2合并生脉注射液治疗肝癌栓塞化疗后近期疗效、生存率及免疫功能变化等临床指标.方法 采用已确诊的原发性及转移性肝癌144例,随机分为治疗组及对照组各72例,治疗组在采用肝癌栓塞化疗后即用白介素—220万U肌注,5%GS250ml+生脉注射液40ml静脉滴注,1/日,10～15天为1疗程.对照组仅作栓塞化疗,两组病人行栓塞化疗2～6次不等,间隔时间视病情而定.结果治疗组有效率(CR+PR)为 84.7%(61/72),明显高于对照组(58.3%,42/72);治疗组1年、2年、3年生存率分别为80.5%、66.7%、35.4%,中位生存期为18个月,而对照组分别为47.2%、31.9%.13.8%,中位生存期为10个月,两组比较有非常显著性差异(P<001);自然杀伤细胞(NK)活性、T细胞亚群(CD_3、CD_4、CD_8、CD_4/CD_8)数值,在治疗组明显提高,对照组下降,两组有显著差异性(p<005).结论生脉注射液联合白介素—2治疗肝癌栓塞化疗在有效率、生存率、中位生存期、免疫指标均较单纯塞栓化疗为高,是治疗中晚期肝癌较理想的方法.
Objective To observe the clinical efficacy of interleukin-2 combined with Shengmai injection in the treatment of hepatocellular carcinoma after thromboembolism and chemotherapy.Methods 144 patients with confirmed primary and metastatic HCC were randomly divided into treatment group and control group Group of 72 cases in the treatment group after the use of liver cancer embolization chemotherapy with interleukin -2.2 million U intramuscular injection, 5% GS250ml + Shengmai injection 40ml intravenous infusion, 1 / day, 10 to 15 days for a course of treatment. (P <0.05) .Conclusion The effective rate of treatment group (84.7%) was significantly higher than that of control group (58.3%) %, 42/72). The 1-year, 2-year and 3-year survival rates of the treatment group were 80.5%, 66.7% and 35.4% respectively. The median survival time was 18 months, while the control group was 47.2% and 31.9% respectively. The median survival time was 10 months. There was a significant difference between the two groups (P <0.001). The NK activity and T cell subsets (CD_3, CD_4, CD_8 and CD_4 / CD_8) , Significantly increased in the treatment group, decreased in the control group, significant difference between the two groups (p <005) .Conclusion Shengmai injection combined with interleukin-2 in the treatment of liver cancer embolization chemotherapy in effective rate, Survival rate, median survival and immune indicators were higher than simple plug chemotherapy, is the treatment of advanced liver cancer is a more ideal method.